此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Innovative Non-Invasive Diagnostics and Personalized Treatment Strategies for Endometriosis Through Advanced Multi-Omics and Ultrasound Integration (ENDO-NOVA)

2026年4月29日 更新者:Region Stockholm

Innovativa Icke-invasiva Diagnostiska Och Personliga Behandlingsstrategier för Endometrios Genom Avancerad Multi-omik Och Ultraljudsintegration

Endometriosis is a prevalent gynecological condition affecting approximately 10% of women of reproductive age worldwide. It presents with nonspecific but often severe symptoms, including chronic pelvic pain (in 70% of cases) and infertility (in up to 40% of cases), imposing significant physical, psychological, economic, and societal burdens. Despite its widespread occurrence, the exact etiology and pathogenesis of endometriosis remain unclear, and no definitive cure exists. Early diagnosis and management are crucial for improving patient outcomes; however, major diagnostic delays persist. Current imaging techniques such as transvaginal ultrasound (TVUS) examination and magnetic resonance imaging, along with biochemical markers lack sufficient specificity. Consequently, confirmation of diagnosis still requires surgical procedures under general anesthesia, i.e.

laparoscopy ("key-hole surgery") and tissue biopsy. This delay exacerbates the disease burden and healthcare costs, underscoring the urgent need for non-invasive, precise diagnostic strategies. This project proposes a multi-modal approach integrating advanced ultrasound imaging with novel biomarkers identified via comprehensive multi-omics analyses, including proteomics, transcriptomics, and immune profiling, of patient-derived endometrial organoids. It aims to understand the underlying mechanisms of reduced endometrial receptivity of embryos in patients with endometriosis. Additionally, we will explore personalized treatment strategies by utilizing patient-specific organoids for drug screening and evaluation of treatment response.

This project aims to develop a non-invasive diagnostic strategy by integrating:

  1. AI-enhanced TVUS for improved lesion detection.
  2. Multi-omics biomarker discovery through proteomics, transcriptomics, and immune profiling.
  3. Underpinning the mechanisms of reduced endometrial receptivity in endometriosis using an in vitro model of embryo-endometrium interaction.
  4. Endometrial organoid models to enable precision medicine-based drug testing. The development of a reliable noninvasive or minimally invasive diagnostic test-or a combination of tests-could revolutionize the diagnostic pathway by reducing delays, avoiding the need for surgery, and facilitating disease monitoring and treatment evaluation.

研究概览

研究类型

观察性的

注册 (估计的)

365

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

不适用

取样方法

概率样本

研究人群

Women aged 18-45 years with suspected or confirmed endometriosis that visit the Endometriosis Centre at the Gynaecology Department at Karolinska University Hospital (KUS), Huddinge

描述

Inclusion Criteria:

  • Women aged 18-45
  • Understands and speaks the Swedish language
  • Suspected or confirmed endometriosis

Exclusion Criteria:

  • Do not have a uterus

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
1
Never had treatment
Diagnosis using AI-enhanced transvaginal ultrasound, multi-omics, and organoids
2
Ongoing treatment
Diagnosis using AI-enhanced transvaginal ultrasound, multi-omics, and organoids
3
No actual treatment (has had treatment before)
Diagnosis using AI-enhanced transvaginal ultrasound, multi-omics, and organoids

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Diagnostic accuracy of the combined AI-assisted transvaginal ultrasound and multi-omics biomarker model for detection of endometriosis
大体时间:At baseline diagnostic evaluation
Sensitivity and specificity of a combined diagnostic model integrating AI-assisted interpretation of transvaginal ultrasound images with plasma, saliva, urine, and endometrial-derived biomarkers for the detection of endometriosis, using laparoscopic diagnosis with or without histological confirmation as the reference standard.
At baseline diagnostic evaluation

次要结果测量

结果测量
措施说明
大体时间
Diagnostic accuracy of AI-assisted transvaginal ultrasound alone
大体时间:Baseline
To evaluate the performance of AI-assisted transvaginal ultrasound (TVUS) for detection and classification of endometriosis lesions.
Baseline
Diagnostic performance of plasma and endometrial biomarker panel
大体时间:Baseline sample collection
To assess the ability of plasma and endometrial-derived biomarkers to detect endometriosis, disease stage, and correlate to clinical symptoms.
Baseline sample collection
Implantation rate in in vitro endometrial models
大体时间:Periprocedural/ During in vitro culture period (e.g., up to 5-10 days)
To compare the attachment rate of embryo-derived or stem cell-derived embryonic structures (blastoids) to endometrial tissue from women with and without endometriosis.
Periprocedural/ During in vitro culture period (e.g., up to 5-10 days)
Molecular characteristics associated with embryo/blastoid attachment
大体时间:Periprocedural/During in vitro experiments
To evaluate transcriptomic and hormonal differences between successfully and unsuccessfully attaching embryos or blastoids.
Periprocedural/During in vitro experiments
Organoid drug response variability and association with disease characteristics
大体时间:At baseline sample collection and through study completion (around 3 years)
To evaluate variability in response to hormonal and immune-targeted therapies in organoids and association with disease severity.
At baseline sample collection and through study completion (around 3 years)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Ronak Perot, MD、Region Stockholm
  • 学习椅:Lars Henningsohn, MD,Prof、Karolinska Institutet

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年4月20日

初级完成 (估计的)

2028年4月20日

研究完成 (估计的)

2029年4月20日

研究注册日期

首次提交

2026年4月13日

首先提交符合 QC 标准的

2026年4月29日

首次发布 (实际的)

2026年5月6日

研究记录更新

最后更新发布 (实际的)

2026年5月6日

上次提交的符合 QC 标准的更新

2026年4月29日

最后验证

2026年4月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅